Why Does the FDA Want to Stop Improving Medicines via Patent ‘Areas of Concern’?

Andrei Iancu

11.2021

Andrei Iancu co-authored the article, “Why Does the FDA Want to Stop Improving Medicines via Patent ‘Areas of Concern’?” with a fellow former director of the USPTO David Kappos, which was published in STAT on November 8.

Please click here to view the article (subscription required).